Wearing a mask does cause an increase in report errors with speech-recognition software, but the mistakes are small and unlikely to cause a negative impact.
Wearing a surgical mask while using speech recognition to complete a radiology report does lead to a higher dictation error rate – but, don’t worry. Most mistakes are minor are unlikely to negatively impact care.
Masks have become a necessary and ubiquitous part of healthcare throughout the COVID-19 pandemic, and some in the industry have worried that wearing a mask while using speech-recognition software could open the door for unintended errors.
In a poster presented during the Society for Imaging Informatics in Medicine (SIIM) 2021 Virtual Annual Meeting, Abiola Femi-Abodunde, M.D., a diagnostic radiology resident from the University of North Carolina at Chapel Hill School of Medicine, revealed that masks do cause a 25-percent increase is dictation errors, but they’re small.
“There is a near-significant increase in the rate of dictation errors in unedited radiologist reports created with speech-recognition software, a difference which may be accentuated in some groups of radiologists,” she said. “However, most errors are minor single-word errors and are unlikely to result in a medically relevant misunderstanding.”
For more SIIM 2021 coverage, click here.
For this study, the team created 40 model radiology reports that simulated radiographic/fluoroscopic, ultrasound, CT, and MRI imaging reports that are typically captured in academic medical centers. Six radiologists, who were randomly assigned to masked and unmasked groups, used speech-recognition software to dictate those reports. Their versions were, then, compared to the models, and the team classified any errors by type and severity.
According to their analysis, the overall dictation error rate was 25-percent higher when radiologists wore masks. Specifically, masked providers made 27.1 +/- 2.2 errors per 1,000 words compared with the 21.7 +/- 4.9 errors per 1,000 words from unmasked providers. But, after excluding one trainee with an accented speech pattern, the overall error rate fell to a 19-percent increase while masked – 20.1 +/- 2.2 errors per 1,000 words during masking and 16.9 +/- 1.9 errors per 1,000 words unmasked. Of the unmasked errors, she said, 58 percent were minor, as were 56 percent of those occurring while masked.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.